Jump to content

Baden-Württemberg and Alsace to cooperate in the life sciences sector

The Alsace BioValley biotech and health cluster and BIOPRO Baden-Württemberg signed a memorandum of understanding on 9th January 2014 whose objective is to further expand the excellent cooperation between the two regions.

Dr. Ralf Kindervater, BIOPRO Baden-Württemberg, and Didier Frommweiler, Alsace BioValley, signing the memorandum and laying the foundation for expanding the successful cooperation between the two organisations. © BIOPRO/nw

Baden-Württemberg and Alsace are strong regions in the field of pharmaceutical biotechnology and medical technology, both in terms of scientific excellence and economic power. Alongside Switzerland, the two regions in the heart of Europe are among the world's economic powerhouses. Both regions can benefit from one another’s strengths by fostering innovation through cooperation between companies and research institutions in the life sciences sector.

Under the agreement, BIOPRO Baden-Württemberg and Alsace BioValley will support companies and research institutions in their search for suitable partners and in creating impulses by organising joint events and initiating projects that are eligible for EU funding. “The successful long-standing cooperation between the two organisations in the EU-funded trinational BioValley cluster has laid an excellent foundation and brought together numerous partners from research and industry from both sides of the Rhine. “We would like to build on this in the future as well as exploiting the synergies between the two regions to a greater and better extent than before,” said Dr. Ralf Kindervater, CEO of BIOPRO Baden-Württemberg, at the signing of the bilateral agreement. 

Didier Frommweiler, managing director of Alsace BioValley, adds: “Our regions also plan to work more closely together in drug research and development. The French-German Advanced Translational drug discovery Center (FGATC), which is currently being established, is a public-private partnership that brings together the University of Strasbourg, the French Institute of Health and Medical Research (INSERM), the Helmholtz Association, the University Hospital of Heidelberg, the DKFZ and Sanofi. It is open to further industrial partners from Baden-Württemberg. This is an excellent opportunity for companies on either side of the Rhine and the Alsace BioValley and BIOPRO will actively support the project.” The project will be supported by German and French funding. There will initially be four new thematic drug discovery projects per year, later increasing to eight. Some of these projects will be German. 

The cooperation between the two organisations in the life sciences sector offers great opportunities for companies and research institutions from the two regions. F.l.t.r.: Jürgen Oswald, bwi; Dr. Ralf Kindervater and Dr. Barbara Jonischkeit, BIOPRO BW; Didier Frommweiler, Mona Boyé and Agnès Legoll, Alsace BioValley. © BIOPRO/nw
Alsace BioValley (ABV)
ABV is a French biotechnology and health cluster whose objective is to drive forward innovations in Alsace (France). ABV supports life sciences and healthcare companies in the development of R&D projects and the initiation of national and international partnerships in the fields of drug development and medical technology. In addition, ABV is actively engaged in providing its member companies with access to venture capital and public funding.

BIOPRO Baden-Württemberg 
BIOPRO Baden-Württemberg GmbH is a state-wide service agency focussed on fostering innovation in the healthcare industry, including the medical technology, biotechnology and pharmaceutical industry sectors, and establishing a bioeconomy in Baden-Württemberg. 
Website address: https://www.bio-pro.de/en/press/press-release/baden-wuerttemberg-and-alsace-to-cooperate-in-the-life-sciences-sector